NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

特發性肺纖維化(IPF):到2029年的機會分析和預測

Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecasts to 2029 (Event Driven Update)

出版商 GlobalData 商品編碼 970308
出版日期 內容資訊 英文 121 Pages
訂單完成後即時交付
價格
特發性肺纖維化(IPF):到2029年的機會分析和預測 Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecasts to 2029 (Event Driven Update)
出版日期: 2021年04月15日內容資訊: 英文 121 Pages
簡介

特發性肺纖維化(IPF)市場的增長因素包括尋求滿足臨床未滿足需求的製藥公司批准的有益治療方法以及當前治療方法。預計在預測期內,新產品的傳播和批准將是市場增長的主要動力。

本報告研究了七個主要國家(美國,EU5,日本)的特發性肺纖維化(IPF)市場,包括疾病概述,流行病學,COVID-19效應,未滿足的需求和機會。並提供有關策略,管道評估分析等的信息。

目錄

第1章目錄

  • 表列表
  • 圖片清單

第2章執行摘要

  • IPF市場預測期內的適度增長
  • 需要夥伴關係來維持創新型小型製藥公司的發展
  • 未滿足的需求很高
  • 後期管道創新在許多不同的作用機制中
  • 醫生的觀點

第3章簡介

  • 催化劑
  • 相關報告
  • 未來相關報告

第4章疾病概述

  • 病因與病理生理
    • 病因
    • 病理生理學
  • 分類或分期系統
    • GAP模型
    • 由於努力肺活動(FVC)減少而導致的層次結構

第5章流行病學

  • 疾病背景
  • 危險因素和合併症
  • 世界趨勢
  • 預測調查方法
  • IPF流行病學預測(2019-2029)
    • 被診斷為IPF的病例
    • IPF的性別診斷案例
    • IPF特定年齡的診斷病例
    • 經診斷的IPF患病率
    • 性別:診斷為IPF的患病率
    • 按年齡分類:IPF診斷患病率
    • 嚴重程度:IPF常見病例的診斷
    • 通過合併症:IPF常見病例的診斷
    • IPF的總患病率
  • 討論
    • 對流行病學預測的見解
    • COVID-19的影響
    • 分析極限
    • 分析優勢

第6章當前的治療方法

  • 概述
  • 當前治療指南
  • 對症治療

第7章未滿足的需求和機會的評估

  • 概述
  • 早期診斷
  • 提高藥物安全性和功效
  • 改善患者的生活質量
  • 重病患者的治療

第8章研發策略

  • 概述
    • 企業聯盟
    • 聯合療法
  • 臨床試驗設計
    • 適當的端點
    • 越來越多地使用生活質量測量
    • 附加標準治療
    • 選擇患者人群

第9章COVID-19對IPF疾病空間的影響

  • 概述
  • 護理的連續性
  • 試用物流
  • 對病態空間的長期影響

第10章管道評估

  • 概述
  • 創新的早期方法

第11章管道評估分析

  • 主要管道藥物的臨床基準
  • 主要管道藥品的商業基準
  • 競爭評估
  • 主要線路的10年預測
    • 美國
    • 歐盟5個國家
    • 日本

第12章附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC122POA

Idiopathic pulmonary fibrosis (IPF) is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs). Idiopathic pulmonary fibrosis (IPF) is a new and rapidly-establishing market, which, before 2011 was non-existent, with no approved pharmaceutical treatments for the chronic, debilitating disease, which has an abysmal prognosis. However, the last decade has seen a period of explosive growth in the IPF market following the entry of two pharmacological small molecule treatments; Roche's Esbriet and Boehringer Ingelheim's Ofev. The landscape will continue to evolve and the increasing uptake of current therapies and approval of new products will be the primary drivers of growth over the forecast period.

The catalyst for this event-driven update is the discontinuation of GLPG-1690 by Gilead/Galapagos for development in all indications, including IPF and Systemic Sclerosis (SSc) in Q1 2021. Due to IPF's high clinical unmet needs, the discontinuation of GLPG-1690 represents a major setback in the disease space, since ziritaxestat was expected to be the first late-state pipeline product to launch for IPF in the next several years. The next earliest pipeline agent set to launch is pamrevlumab in 2024.

Key Highlights

  • The greatest drivers of growth in the global IPF market include the launch of six new pipeline therapies during the forecast period and an increasing diagnosed prevalence in many 7MM countries.
  • The main barriers to growth in the IPF market include low diagnostic and treatment rates and the patent expiries of both Ofev and Esbriet in all markets.
  • The late-stage pipeline products are completely distinct mechanisms of action both from each other and the available marketed therapies.
  • The most important unmet needs in the IPF market are improved drug safety and efficacy and improvement in patient quality of life.

KEY QUESTIONS ANSWERED

  • Which unmet needs are limiting the treatment of IPF in the 7MM?
  • What strategies can the pharmaceutical industry employ to increase treatment rates for IPF? How should these strategies differ across different geographical markets?
  • What effect will the launch of generics have on the sales of branded agents?
  • What are the main R&D trends in the IPF market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?
  • What was the impact of the COVID-19 pandemic on the IPF treatment, clinical trial conduct, and looking forward?

Scope

  • Overview of IPF including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline IPF market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting IPF therapeutics sales in the 7MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global IPF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global IPF therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global IPF market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global IPF therapeutics market from 2019-2029.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Idiopathic Pulmonary Fibrosis: Executive Summary

  • 2.1 IPF Market to Experience Conservative Growth over the Forecast Period
  • 2.2 Innovative Small Pharma Require Partnerships to Sustain Development
  • 2.3 High Unmet Clinical Needs Remain
  • 2.4 Late-Stage Pipeline Fractured Among Many Differing Mechanisms of Action
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification or Staging Systems
    • 4.2.1 GAP Model
    • 4.2.2 Stratification by Decline in Forced Vital Capacity (FVC)

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources Used
    • 5.4.2 Forecast Assumptions and Methods
  • 5.5 Epidemiological Forecast for IPF (2019-2029)
    • 5.5.1 Diagnosed Incident Cases of IPF
    • 5.5.2 Sex-Specific Diagnosed Incident Cases of IPF
    • 5.5.3 Age-Specific Diagnosed Incident Cases of IPF
    • 5.5.4 Diagnosed Prevalent Cases of IPF
    • 5.5.5 Sex-Specific Diagnosed Prevalent Cases of IPF
    • 5.5.6 Age-Specific Diagnosed Prevalent Cases of IPF
    • 5.5.7 Diagnosed Prevalent Cases of IPF by Severity
    • 5.5.8 Diagnosed Prevalent Cases of IPF by Comorbidities
    • 5.5.9 Total Prevalent Cases of IPF
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Coronavirus Disease 2019 (COVID-19) Impact
    • 5.6.3 Limitations of Analysis
    • 5.6.4 Strengths of Analysis

6 Current Treatment Options

  • 6.1 Overview
  • 6.2 Current Treatment Guidelines
  • 6.3 Symptomatic Treatments

7 Unmet Needs and Opportunity Assessment

  • 7.1 Overview
  • 7.2 Earlier Diagnosis
  • 7.3 Improved Drug Safety and Efficacy
  • 7.4 Improvement in Patient Quality of Life
  • 7.5 Treatments for Patients with Severe Disease

8 R&D Strategies

  • 8.1 Overview
    • 8.1.1 Corporate Partnerships
    • 8.1.2 Combination Therapy
  • 8.2 Clinical Trial Design
    • 8.2.1 Appropriate Endpoints
    • 8.2.2 Increased Use of Quality of Life Measures
    • 8.2.3 Add-Ons to Standard of Care
    • 8.2.4 Selection of Patient Population

9 Impact of COVID-19 on the IPF Disease Space

  • 9.1 Overview
  • 9.2 Continuity of Care
  • 9.3 Trial Logistics
    • 9.3.1 Recruitment
    • 9.3.2 Trial Conduct in Isolation
    • 9.3.3 Supply Chain
  • 9.4 Long-Term Impact on the Disease Space

10 Pipeline Assessment

  • 10.1 Overview
  • 10.2 Innovative Early-Stage Approaches

11 Pipeline Valuation Analysis

  • 11.1 Clinical Benchmark of Key Pipeline Drugs
  • 11.2 Commercial Benchmark of Key Pipeline Drugs
  • 11.3 Competitive Assessment
  • 11.4 Top-Line 10-Year Forecast
    • 11.4.1 US
    • 11.4.2 5EU
    • 11.4.3 Japan

12 Appendix

  • 12.1 Bibliography
  • 12.2 Abbreviations
  • 12.3 Methodology
    • 12.3.1 Forecasting Methodology
    • 12.3.2 Diagnosed Patients
    • 12.3.3 Percent Drug-Treated Patients
    • 12.3.4 Drugs Included in Each Therapeutic Class
    • 12.3.5 Launch and Patent Expiry Dates
    • 12.3.6 General Pricing Assumptions
    • 12.3.7 Individual Drug Assumptions
    • 12.3.8 Generic Erosion
    • 12.3.9 Pricing of Pipeline Agents
  • 12.4 Primary Research - KOLs Interviewed for This Report
    • 12.4.1 KOLs
    • 12.4.2 Payers
  • 12.5 Primary Research - Prescriber Survey
  • 12.6 About the Authors
    • 12.6.1 Analyst
    • 12.6.2 Therapy Area Director
    • 12.6.3 Epidemiologist
    • 12.6.4 Managing Epidemiologist
    • 12.6.5 Global Director of Therapy Analysis and Epidemiology
    • 12.6.6 Global Head and EVP of Healthcare Operations and Strategy
  • 12.7 About GlobalData
  • 12.8 Contact Us
  • 12.9 Disclaimer

List of Tables

List of Tables

  • Table 1: IPF: Key Metrics in the 7MM
  • Table 2: The GAP Index
  • Table 3: Risk Factors and Comorbidities for IPF
  • Table 4: Diagnosed Prevalent Cases of IPF by Comorbidities, N, Both Sexes, Ages ≥18 Years, 2019
  • Table 5: Treatment Guidelines for IPF, 2020
  • Table 6: Leading Treatments for IPF, 2020
  • Table 7: Early Stage Pipeline Agents for IPF, 2020
  • Table 8: Clinical Benchmark of Key Pipeline Drugs - IPF
  • Table 9: Commercial Benchmark of Key Pipeline Drugs - IPF
  • Table 10: IPF Market - Global Drivers and Barriers, 2019-2029
  • Table 11: Key Events Impacting US Sales for IPF, 2019-2029
  • Table 12: Key Events Impacting 5EU Sales for IPF, 2019-2029
  • Table 13: Key Events Impacting Japan Sales for IPF, 2019-2029
  • Table 14: Key Historical and Projected Launch Dates for IPF
  • Table 15: Key Historical and Projected Patent Expiry Dates for IPF
  • Table 16: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: Global Sales Forecast by Country for IPF in 2019 and 2029
  • Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care (SOC), Esbriet and Ofev
  • Figure 3: The Induction and Progression of IPF
  • Figure 4: 7MM, Diagnosed Incidence of IPF (Cases per 100,000 Population), Both Sexes, Ages ≥18 Years, 2019
  • Figure 5: 7MM, Diagnosed Prevalence of IPF, Both Sexes, Ages ≥18 Years, 2019
  • Figure 6: 7MM, Total Prevalence of IPF, Both Sexes, Ages ≥18 Years, 2019
  • Figure 7: 7MM, Sources Used and Not Used to Forecast the Diagnosed Incident and Diagnosed Prevalent Cases of IPF
  • Figure 8: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of IPF by Severity
  • Figure 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of IPF by Comorbidities
  • Figure 10: 7MM, Diagnosed Incident Cases of IPF, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 11: 7MM, Diagnosed Incident Cases of IPF, N, by Sex, Ages ≥18 Years, 2019
  • Figure 12: 7MM, Diagnosed Incident Cases of IPF by Age, N, Both Sexes, 2019
  • Figure 13: 7MM, Diagnosed Prevalent Cases of IPF, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 14: 7MM, Diagnosed Prevalent Cases of IPF, N, by Sex, Ages ≥18 Years, 2019
  • Figure 15: 7MM, Diagnosed Prevalent Cases of IPF by Age, N, Both Sexes, 2019
  • Figure 16: 7MM, Diagnosed Prevalent Cases of IPF by Severity, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 17: 7MM, Total Prevalent Cases of IPF, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 18: Unmet Needs and Opportunities in IPF
  • Figure 19: Overview of the Development Pipeline in IPF
  • Figure 20: Key Phase II/III Trials for Therapeutic Agents that Target IPF Disease Progression
  • Figure 21: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care (SOC)
  • Figure 22: Global (7MM) Sales Forecast by Country for IPF in 2019 and 2029
  • Figure 23: Global Sales Forecast by Molecule for IPF in 2019 and 2029
  • Figure 24: Sales Forecast by Class for IPF in the US in 2019 and 2029
  • Figure 25: Sales Forecast by Class for IPF in the 5EU in 2019 and 2029
  • Figure 26: Sales Forecast by Class for IPF in Japan in 2019 and 2029